Cardiac cell therapy: lessons from clinical trials (Q37769840)

22 August 2017

1 reference

title

Cardiac cell therapy: lessons from clinical trials (English)

1 reference

22 August 2017

Philippe Menasche

1

1 reference

22 August 2017

30 June 2010

1 reference

Journal of Molecular and Cellular Cardiology

22 August 2017

1 reference

22 August 2017

50

1 reference

22 August 2017

258-265

1 reference

22 August 2017

2

1 reference

Autologous bone marrow stem cells to treat acute myocardial infarction: a systematic review

22 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intracoronary Bone Marrow–Derived Progenitor Cells in Acute Myocardial Infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Bone marrow cell therapy after acute myocardial infarction: the HEBE trial in perspective, first results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Int

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Effects of intracoronary injection of mononuclear bone marrow cells on left ventricular function, arrhythmia risk profile, and restenosis after thrombolytic therapy of acute myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Results of intracoronary stem cell therapy after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Granulocyte colony-stimulating factor therapy for cardiac repair after acute myocardial infarction: a systematic review and meta-analysis of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intramyocardial bone marrow cell injection for chronic myocardial ischemia: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Four-year follow-up of treatment with intramyocardial skeletal myoblasts injection in patients with ischaemic cardiomyopathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cell-based therapy for heart disease: a clinically oriented perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

A pilot trial to assess potential effects of selective intracoronary bone marrow-derived progenitor cell infusion in patients with nonischemic dilated cardiomyopathy: final 1-year results of the transplantation of progenitor cells and functional reg

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intramyocardial delivery of CD133+ bone marrow cells and coronary artery bypass grafting for chronic ischemic heart disease: safety and efficacy studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Red blood cell contamination of the final cell product impairs the efficacy of autologous bone marrow mononuclear cell therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Proteomic analysis reveals presence of platelet microparticles in endothelial progenitor cell cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Randomized study of mononuclear bone marrow cell transplantation in patients with coronary surgery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Five-year follow-up after transepicardial implantation of autologous bone marrow mononuclear cells to ungraftable coronary territories for patients with ischaemic cardiomyopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Pilot trial on determinants of progenitor cell recruitment to the infarcted human myocardium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Antiarrhythmic engineering of skeletal myoblasts for cardiac transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Direct intramyocardial but not intracoronary injection of bone marrow cells induces ventricular arrhythmias in a rat chronic ischemic heart failure model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Electrophysiological challenges of cell-based myocardial repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Mobilized bone marrow progenitor cells serve as donors of cytoprotective genes for cardiac repair

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Role of host tissues for sustained humoral effects after endothelial progenitor cell transplantation into the ischemic heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Determinants of functional recovery after myocardial infarction of patients treated with bone marrow-derived stem cells after thrombolytic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Long-term effects of intracoronary bone marrow cell transfer on diastolic function in patients after acute myocardial infarction: 5-year results from the randomized-controlled BOOST trial--an echocardiographic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Intracoronary administration of autologous adipose tissue-derived stem cells improves left ventricular function, perfusion, and remodelling after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Mesenchymal stem cells as trophic mediators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Pretreatment of adult bone marrow mesenchymal stem cells with cardiomyogenic growth factors and repair of the chronically infarcted myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

7 January 2021

Human cardiac stem cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cardiac stem cells in the real world

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Impaired angiogenic potency of bone marrow cells from patients with advanced age, anemia, and renal failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Selective functional exhaustion of hematopoietic progenitor cells in the bone marrow of patients with postinfarction heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Transcoronary transplantation of functionally competent BMCs is associated with a decrease in natriuretic peptide serum levels and improved survival of patients with chronic postinfarction heart failure: results of the TOPCARE-CHD Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Mesenchymal stem cells avoid allogeneic rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Mesenchymal stem cells: a new strategy for immunosuppression?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Although pig allogeneic mesenchymal stem cells are not immunogenic in vitro, intracardiac injection elicits an immune response in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Magnetic targeting enhances engraftment and functional benefit of iron-labeled cardiosphere-derived cells in myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Monitoring of bone marrow cell homing into the infarcted human myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Stem cells for myocardial repair with use of a transarterial catheter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Focused ultrasound-induced stimulation of microbubbles augments site-targeted engraftment of mesenchymal stem cells after acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Ex vivo delivered stromal cell-derived factor-1alpha promotes stem cell homing and induces angiomyogenesis in the infarcted myocardium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cardiomyocyte grafting for cardiac repair: graft cell death and anti-death strategies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Pharmacologically preconditioned skeletal myoblasts are resistant to oxidative stress and promote angiomyogenesis via release of paracrine factors in the infarcted heart

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

A new direction for cardiac regeneration therapy: application of synergistically acting epicardium-derived cells and cardiomyocyte progenitor cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Enhancing efficacy of stem cell transplantation to the heart with a PEGylated fibrin biomatrix.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cardiac progenitor cells and biotinylated insulin-like growth factor-1 nanofibers improve endogenous and exogenous myocardial regeneration after infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Engineered heart tissue grafts improve systolic and diastolic function in infarcted rat hearts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Cell delivery: intramyocardial injections or epicardial deposition? A head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

Improved regional function after autologous bone marrow-derived stem cell transfer in patients with acute myocardial infarction: a randomized, double-blind strain rate imaging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YJMCC.2010.06.010

10.1016/J.YJMCC.2010.06.010

7 January 2021

Identifiers

DOI

1 reference

22 August 2017

1 reference

PubMed ID

20600097